anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an antitumor agent and a pharmacological composition of anticancer activity that shows an effective antitumor activity in vivo and is safe for living bodies.  &lt;P&gt;SOLUTION: This medicine is an antitumor agent and a pharmacological composition of antitumor activity containing a pyrvinium compound, particularly pyrvinium pamoate. The active ingredient has a chemical structure of 6-dimethylamino-2-[2-(2,5-dimethyl-1-phenyl-3-pyrilyl)vinyl]-1-methyl-quinolinium pamoate. The pyrvinium pamoate that is an active ingredient for the anticancer agent and the pharmacological composition for anticancer activity reveals extremely high toxicity against glucose-starved in vivo cancer cells. In addition, the pyrvinium pamoate is already administered into human body as parasiticide whereby it can safely be given into human bodies as an anticancer agent or a pharmacological composition for antitumor activity in vivo.  &lt;P&gt;COPYRIGHT: (C)2004,JPO&amp;NCIPI
Self-assembling peptides or self-assembling peptidomimetics (&#34;SAPs&#34;) can treat inflammation or inflammatory diseases, or alleviate one or more symptoms of diseases and disorders associated with undesirable inflammation. Topical and injectable compositions of SAPs for topical administration to sites of inflammation to reduce or prevent symptoms of inflammatory diseases and disorders are described. These compositions comprise one or more SAPs in an amount and concentration effective to reduce or prevent one or more symptoms of the undesired inflammation. The SAP may be assembled before or after the composition is applied. The SAP forms structures within or on the body surface that prevent and/or reduce symptoms associated with inflammatory and other dysregulated immune processes. These peptides may assemble upon contact with bodily fluids (e.g., synovial fluid), or may be contacted with an ionic solution to begin assembly.
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain an ocular medicinal composition for dry eyes staying on the cornea and exhibiting water holding effects over a longer period.  &lt;P&gt;SOLUTION: The ocular medicinal composition comprises acetylated hyaluronic acid and a pharmaceutically acceptable carrier. The average molecular weight of the acetylated hyaluronic acid is preferably 10,000-1,000,000 and the number of substitution of acetyl groups is preferably 2.5-4.5. In a preferred mode, the ocular medicinal composition is utilized for therapy or prophylaxis of the dry eyes. In a more preferred mode, the composition is eye drops for the dry eyes.  &lt;P&gt;COPYRIGHT: (C)2004,JPO&amp;NCIPI
The application provides novel neuroactive fragments of human amyloid pre cursor protein (APP). The fragments include sequence from the A.beta. region of APP but also extend upstream. The fragments are soluble in aqueous solut ion most bands are about 10 kDa and above and do not correspond with the exp ected molecular weight of a dimer or trimer. The fragments and sub fragments thereof can be used as immunogens in methods of immunotherapy to treat Alzh eimer&#39;s and other amyloidogenic diseases characterized by deposits of A.beta . in the brain. Antibodies to the part of the fragment upstream from APP or the interface between A.beta. and the upstream sequence can also be used in such therapeutic method. The fragments are also useful as markers, which can be detected for diagnosis or prognosis of disease or for screening agents.&lt; /SDOAB&gt;
A pull-type V-rake apparatus for use in raking cut vegetation. The V-rake is comprised of a left hand, side discharge, wheel rake assembly and a right hand, side discharge, wheel rake assembly operably connected by a forward pivotal subframe and a rearward pivotal subframe for use as a single implement. The left and right hand rake assemblies are hydraulically actuated to fold from an operative field position to a transport position. The transport profile being narrow enough to be pulled behind the farm vehicle down a roadway. When the V-rake is in its operative field position, the left and right wheel rake assemblies form a &#34;V&#34;. The cut vegetation is raked inwardly and rearwardly on the right side and the left side discharging the cut vegetation in the middle at the apparent vertex of the rakes to produce a single larger windrow as the V-rake traverses the field. The wheel rakes on the wheel rake assemblies are vertically adjustable from a transport position to an operative field position and are spring biased thereby enabling each wheel rake to articulate along a vertical arc when encountering an obstruction. The rake assemblies are able to articulate front-to-rear and side-to-side allowing the wheel rakes to maintain substantial contact with the cut vegetation at all times to ensure that no cut vegetation will be skipped as the V-rake traverses uneven terrain.
An emergency patient management system and a method thereof using an RFID tag are provided to manage a position of a doctor by using the RFID tag, thereby confirming a call/response state of the doctor quickly when a call is made from an emergency room. When an RFID tag decides that a patient leaves an emergency room, an entrance information management system(10) outputs location information and an ID of the RFID tag. A tag information manager(12) manages the RFID ID toward an identifier of the RFID tag. An event sensor(16) extracts the RFID identifier and an entrance detection sensor ID from an RFID tag signal received through an AP(Access Point). An entrance information manager(14) generates RFID tag location information where a location of the RFID tag is displayed on a map. An emergency patient safety management system(20&#39;) outputs a state that a patient leaves an emergency room, on a display unit(30).
PCT No. PCT/SE96/01428 Sec. 371 Date May 7, 1998 Sec. 102(e) Date May 7, 1998 PCT Filed Nov. 6, 1996 PCT Pub. No. WO97/17612 PCT Pub. Date May 15, 1997A method for identification of an infant being particularly susceptible to sudden infant death syndrome (SIDS) comprises the determination of an Helicobacter pylori infection in the infant&#39;s mother, particularly by detection of antibodies to H. pylori of the IgG type, in a blood sample drawn from the infant&#39;s mother or by determination of carbon dioxide formed from urea in the air exhaled from the infant&#39;s mother upon oral administration of a challenge dose of urea. Also disclosed is the use of an antibiotic effective against H. pylori for the manufacture of a medicament for administration to mothers and other persons infected by H. pylori and coming into close bodily contact with infants below two years of age, and a method of prevention of SIDS by administration of that antibiotic.
A transdermal patch is provided for use during oil delivery to a user&#39;s skin. The patch has a first foam member and a second foam member positioned adjacent the first foam member. An adhesive member is attached to the second foam member for securing the patch to a user&#39;s skin. A release liner covers and extends across the adhesive member. A gap can be formed between the first foam member and the second foam member and surrounds the first foam member. The first foam member has a thickness which is greater than a thickness of the second foam member.
PURPOSE:The titled pharmaceutical preparation containing ignavine and/or its acid addition salt. CONSTITUTION:An antiallergic containing a compound shown by the formula (alkaloid contained in Aconitum japonicum Thumb.; melting point: 228-230 deg.C; having improved antipyretic, analgesic, and anti-inflammatory action) and/or its acid addition salt (e.g., inorganic acid salt such as hydrochloride, sulfate, etc., organic acid salt such as maleate, fumarate, etc.) as an active ingredient. The dosage form is a medicine for internal use such as tablet, powder, capsule, injection, a medicine for external use, etc. A dose is 100mg/time in the case of oral administration, and &lt;=4mg/time in the case of injection. The compound shown by the formula inhibits delayed type allergic reactions (e.g., tuberculin type reaction, allotransplantation rejection, contagious hypersensitivity reaction of the skin, etc.) in the strongest way.
126,501. Ehrhardt, P. May 28, 1918. Protective fi l m s ; modicines, administering. - Flexible occlusive surgical dressings of the type consisting of paraffin wax prepared by the addition of resins with or without antisepties &amp;c. are made up in the form of candles with wicke so that the material is readily melted and applied. The candles may be of various crosssections and may have a single wick placed axially or eccentrically, or may have two or more wicks. The melted material may be applied by means of the end of the candle as indicated in Fig. 7, or may be applied by means of a brush. The candles are sterilized during manufacture by raising the temperature of the melted substance, and are cooled in an antiseptic atmosphere such as formaldehyde. The candles are coated with paraffined paper or with a solution of lacquer, wax, resin, cellulose acetate, or a volatile solvent such as alcohol. Suitable additions to the paraffin are rubber or latex, and antiseptics or medicaments such as collorgol, salol, gomenol, pyrogallic acid, chrysophanic acid, or dermatol.
The present invention relates to a novel glial cell line-derived neurotrophic factor receptor beta (GDNFR-β) and novel glial cell line-derived neurotrophic factor receptor gamma 1 and 2 (GDNFR-ηl and GDNFR-η2). The receptors of the present invention share high homology with glial cell line-derived neurotrophic factor receptor alpha and have been named GDNFR-β, GDNFR-η1 and GDNFR-η2. More specifically, isolated nucleic acid molecules are provided encoding human GDNFR-β, GDNFR-η1 and GDNFR-η2 receptors. GDNFR-β, GDNFR-η1 and GDNFR-η2 polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of GDNFR-β, GDNFR-η1 and GDNFR-η2 activity. Also provided are diagnostic and therapeutic methods for disorders and diseases including Parkinson&#39;s disease, thyroid tumor, kidney failure and gut dysfunction.
The present invention relates to organic molecules capable of modulating, regulating and/or inhibiting protein kinase signal transduction. Such compounds are useful for the treatment of diseases related to unregulated protein kinase signal transduction, including cell proliferative diseases such as cancer, atherosclerosis, arthritis and restenosis and metabolic diseases such as diabetes. The present invention features indolinone compounds that potently inhibit protein kinases and related products and methods. Inhibitors specific to the FLK protein kinase can be obtained by adding chemical substituents to the 3-[(indole-3-yl)methylene]-2-indolinone, in particular at the 1&#39; position of the indole ring. Indolinone compounds that specifically inhibit the FLK and platelet derived growth factor protein kinases can harbor a tetrahydroindole or cyclopentano-b-pyrrol moiety. Indolinone compounds that are modified with substituents, particularly at the 5 position of the oxindole ring, can effectively activate protein kinases. This invention also features novel hydrosoluble indolinone compounds that are tyrosine kinase inhibitors and related products and methods.
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to dermatocosmetology, and can be used in treatment of dehydrated involutionally changed face skin in women. For this purpose the first stage successive complex morphofunctional examination of state of moisture-holding structures of epidermal and dermal face skin layers with estimation of their dehydration degree is carried out. First, epidermal layer is examined. If indices of corneal layer moisture degree are lower than 30 conv.units CM, those of moisture-holding function of epidermis are higher than 13 gram/hour/m, degree of relief is higher than 25 conv.units, wrinkling is higher than 20 conv.units, porosity is 23 conv.units, as well as presence of roughness and thinning of epidermis contours, reduction of its echogenesity, smoothing of boundary between epidermis and derma with absence of changes in dermal structures, structural and functional disorders of epidermis with expressed dehydration are diagnosed. After that, state of moisture-holding structures of dermal skin layer is analysed. Degree of its elasticity, presence or absence of homogeneity, thickness and state of dermoepidermal connection are determined. In case of value of dermal structure elasticity indexes lower than 50%, reduction of derma thickness below index value 1.67±0.381, detection of non-homogeneity of dermal structures, development of hypoechogenic zones, structural and functional disorders of derma with expressed dehydration are diagnosed. Then, correction of dehydrated involutionally changed skin is carried out. In case if structural and functional disorders of epidermis are present, preparation &#34;Hyalrepair-07M/mesolift&#34; with concentration of hyaluronic acid 2 mg/ml is introduced intradermally in dose 1 ml on face area 1 time per week, the course includes 5 procedures. In case if structural and functional disorders of derma and epidermis are present, preparation &#34;Hyalrepair-02 bioreparant&#34; with concentration of hyaluronic acid 14 mg/ml is introduced in dose 1 ml on face area 1 time per 3 weeks, the course includes 3 procedures.EFFECT: method ensures obtaining stable and expressed therapeutic effect in case of introduction of hyaluronic acid preparations due to identification and taking into account determined parameters.1 tbl, 2 ex
A method and composition for the inhibition of growth of Salmonella is provided. The effective composition of the invention is a class of fructo-oligosaccharides which inhibit the growth of Salmonella. More particularly, the fructo-oligosaccharides are sucrose molecules having from 1 to 8 fructose residues. This class of sugars is exemplified by &#34;Neosugar&#34; which includes 1-kestose, nystose, and 1-fructofuranosylnystose. The present method includes contacting Salmonella with the effective composition and can include feeding it to a domestic food animal. The present composition includes the effective component and nutritive feed material.
PURPOSE:To obtain the preparation containing an imidazole compound or a salt thereof as an active ingredient. CONSTITUTION:An immune function improver containing a compound [e.g., alpha-(2,4,6-trimethylphenyl)-3-(1-imidazolyl)benzene methanol, etc.] shown by formula (R&lt;1&gt; is H or lower alkyl; both X and Y form oxo or one of X and Y is H and the other is OH; Z is alkyl, cycloalkyl, aryl, etc.) or a salt thereof as an active ingredient. The improver has immune function activating action, immune ability recovering action, macrophage phagocytosis, etc. Oral or parenteral drugs such as tablets, granules, powder, capsules, injection, external preparation, etc., may be cited as the dosage form. A dose is preferably 0.01-50mg/person/day.
An oral preparation contains a water-soluble chlorophyll compound and a higher aliphatic acyl amide of an amino carboxylic acid having 12 to 16 carbon atoms in the higher acyl radical and 2 to 6 carbon atoms in the aliphatic portion of the amino carboxylic acid compound.  The amide may be of formula:  &lt;FORM:0758216/VI/1&gt; where R-CO is a saturated fatty acyl radical containing 12 to 16 carbon atoms e.g. dodecanoyl, tetra and hexadecanoyl radicals; R1 is a hydrogen atom or a lower alkyl group containing 1 to 6 carbon atoms; and X is a hydrogen atom or a cation which forms water-soluble salts e.g. sodium, potassium, ammonium, guanidine, mono-, di- or triethanolamine.  The chlorophyll compound e.g. sodium or potassium copper-, sodium or potassium magnesium-, or sodium iron chlorophyllin, or sodium potassium copper chlorophyll, may be present up to one per cent by weight and the amide up to 5 per cent by weight of the preparation; the ratio by weight of chlorophyll compound to amide being from 1 : 500 to 1 : 2. Suitable amino acids from which the amides may be derived are glycine, sarcasine, alanine, valine, and 3-aminopropanoic acid and specified amides are sodium or potassium N-lauroyl sarcaside and N-lauroyl sarcasine, N-myristoyl sarcaside, N-palmitoyl sarcaside, and N-lauroyl glycide.  The preparation may take the form of toothpaste, cream or powder, liquid dentifrice, mouthwash or tablet.  The pH of the preparation is between 5 and 10.  Other substances which may be present are ethyl alcohol, glycerine, sorbitol, propylene glycol, polyvinylpyrrolidone, sodium carboxymethylcellulose, gum tragacanth, starch, saccharine, urea, bentonite, calcium carbonate, magnesium carbonate, aluminium hydroxide, diammonium phosphate, di and tri-calcium phosphate, alkali metal salts of pyro-, tripoly- and tetraphosphoric acids, ethylene diamine tetracetic and citric acids.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a composition of adhesive agent for being stuck to the skin preventing the peeling during the use, being easily peeled without giving stimulus to the skin when being peeled after a lapse of a prescribed time, and easily peeled with less stimulus to the skin when being peeled a short time after sticking.  &lt;P&gt;SOLUTION: This composition of the adhesive agent for being stuck to the skin includes an adhesive, water absorbent, ceramide and emulsifying agent. This composition of the adhesive agent for being stuck to the skin is so formed that the quantities of the water absorbent, ceramide and emulsifying agent are 10-160 pts.wt., 0.01-3 pts.wt, and 0.03-10 pts.wt. respectively to 100 pts.wt. of the adhesive.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
The present invention relates to an aliphatic acid metabolic imaging agent beta-methyl-15-parafluoro((18)&lt;F&gt; phenyl-pentadecanoic acid and a synthesizing method thereof, particularly to a fluorine-labeled aliphatic acid myocardial metabolism imaging agent. Beta-methyl-phenyl-pentadecanoic acid in the *I-BMIPP structure is used as a precursor and reformed to form the substance (18)&lt;F&gt;-BMFPP of the present invention, and (18)&lt;F&gt;-BMFPP is compound which is independently designed and synthesized by the present invention. Omega bromine undecanoic acid is used as initial raw materials to synthesize BMPPA through polystep reaction. In the present invention, labelled precursor NO2-BMPPA and nonradioactive BMFPP are obtained through the nitration, esterification, reduction, diazotization and diazonium decomposition of BMPPA, and the nucleophilic displacement reaction of the labelled precursor NO2-BMPPA is carried out to synthesize (8)&lt;F&gt;-BMFPP. The present invention improves the iodination method for synthesizing intermediate bodies such as benzene dodecyl iodine and alpha-methyl-benzene tetradecyl iodine. The present invention enhances yield and reduces cost because of the improvement.
1486706 Finishing yarns JOHNSON &amp; JOHNSON 25 Nov 1975 [26 Nov 1974] 48374/75 Headings D1F and D1W Dental floss or tape 10 comprises a twisted or twistless, perhaps coloured, multifilament or staple fibre core thread 11 impregnated and coated with water-insoluble wax 13 containing spray-dried flavour particles 12 which occur on the surface of, or partially embedded in, the wax as well as throughout the filaments. The latter may be of nylon, rayon, polyethylene terephthalate cellulose acetate, polypropylene, cotton or wool. The wax, which may comprise 19-25% by weight of the floss, is preferably white or colourless with a melting point of 140-200‹F e.g. beeswax, paraffin and microcrystalline wax, polyethylene glycols, wax-like resins and polymers, and mixtures thereof. The particles consist of a flavour oil e.g. peppermint, cassia, cinnamon fruits, disposed in a watersoluble matrix material e.g. gums such gum acacia, arabic or tragacanth, starches such as corn starch, or dextrin. In forming the floss the thread is passed through a molten dispersion of the wax and particles to be impregnated &amp;c. therewith, and the thread is thereafter cooled to set the wax.
The present invention relates to novel excretory system related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as &#34;excretory system antigens&#34;, and the use of such excretory system antigens for detecting disorders of the excretory system, particularly the presence of cancer of excretory system tissues and cancer metastases. More specifically, isolated excretory system associated nucleic acid molecules are provided encoding novel excretory system associated polypeptides. Novel excretory system polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human excretory system associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the excretory system, including cancer of excretory system tissues, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.
PROBLEM TO BE SOLVED: To obtain the crystal of the subject compound essentially free from solvent and useful as a pharmaceutical agent such as an antitumor agent by recrystallizing the subject compound in a hydrated alcohol and suspending and stirring the obtained water-ethanol solvated crystal of the subject compound in hot water. SOLUTION: A compound of the formula [ring A may have substitutes; R&lt;1&gt; is H or an N-protecting group; R&lt;2&gt; , R&lt;3&gt; and R&lt;4&gt; are each H, a (halogen- substituted)alkyl, etc.], especially 2-[[3-methyl-4-(2,2,2,-trifluoroethoxy)pyridin-2- yl]methylsulfinyl]benzimidazole is recrystallized from a hydrated alcohol composed of 1pt.vol. of water and 2-30pts.vol. of an alcohol, 1pt. of the obtained solvated compound crystal is suspended in about 2-20pts. of water and stirred for 0.05-5hr while keeping the water temperature between room temperature and 90 deg.C and the obtained desolvated crystal is dried under reduced pressure or in vacuum at about 20-60 deg.C for 5-48hr to obtain the crystal of the objective compound.
PROBLEM TO BE SOLVED: To provide a system and a method for calculating the athletic activity parameters.SOLUTION: A plurality of housings 404 are disposed at a plurality of positions on the user&#39;s body. The plurality of housings are configured to engage with an electronic module 402 removably. The electronic module includes sensors 420, 422, 424 and a processor. The processor is configured to calculate the athletic activity parameters. Each housing is connected with an ID memory 412, or includes an ID memory. The ID memory is saving the information for identifying the place of the housing. The electronic module uses the place information for selecting an algorithm that is used when calculating the athletic activity parameters.SELECTED DRAWING: Figure 4
PURPOSE:To obtain an adsorbent of blood coagulation ninth factor, which is a water-insoluble porous gel having a specific exclusion limit molecular weight, and a sulfur ester group on at least a part of the gel surface. CONSTITUTION:An adsorbent of blood coagulation ninth factor, which is a water-insoluble porous gel (e.g. porous cellulose gel) consisting of hydroxyl group-containing compound having &gt;=50,000, preferably 100,000-2,000,000 exclusion limit molecular weight, and a sulfur ester group on at least a part of the gel surface. By using said adsorbent, a solution containing blood coagulation ninth factor is treated and then the factor is eluted, recovered and readily purified in good yield. The sulfur ester group-containing compound is fixed in water-insoluble porous gel by the bivalent bond and includes sulfated polysaccharide. The blood coagulation ninth factor is useful for treating bleeding of hemophilia B patient.